DE60313595D1 - Verbesserte synthese von cc-1065-analoga - Google Patents

Verbesserte synthese von cc-1065-analoga

Info

Publication number
DE60313595D1
DE60313595D1 DE60313595T DE60313595T DE60313595D1 DE 60313595 D1 DE60313595 D1 DE 60313595D1 DE 60313595 T DE60313595 T DE 60313595T DE 60313595 T DE60313595 T DE 60313595T DE 60313595 D1 DE60313595 D1 DE 60313595D1
Authority
DE
Germany
Prior art keywords
analogue
synthesis
improved synthesis
improved
cbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313595T
Other languages
English (en)
Other versions
DE60313595T2 (de
Inventor
Ravi V J Chari
Robert Yongxin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of DE60313595D1 publication Critical patent/DE60313595D1/de
Application granted granted Critical
Publication of DE60313595T2 publication Critical patent/DE60313595T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Transmission Systems Not Characterized By The Medium Used For Transmission (AREA)
  • Level Indicators Using A Float (AREA)
  • Silicon Polymers (AREA)
DE60313595T 2002-04-05 2003-03-19 Verbesserte synthese von cc-1065-analoga Expired - Lifetime DE60313595T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/116,052 US6534660B1 (en) 2002-04-05 2002-04-05 CC-1065 analog synthesis
US116052 2002-04-05
PCT/US2003/007276 WO2003087055A1 (en) 2002-04-05 2003-03-19 Improved cc-1065 analog synthesis

Publications (2)

Publication Number Publication Date
DE60313595D1 true DE60313595D1 (de) 2007-06-14
DE60313595T2 DE60313595T2 (de) 2008-01-10

Family

ID=22364940

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313595T Expired - Lifetime DE60313595T2 (de) 2002-04-05 2003-03-19 Verbesserte synthese von cc-1065-analoga

Country Status (13)

Country Link
US (3) US6534660B1 (de)
EP (1) EP1492766B1 (de)
JP (1) JP4578105B2 (de)
AT (1) ATE361278T1 (de)
AU (1) AU2003218060B2 (de)
CA (1) CA2456453C (de)
DE (1) DE60313595T2 (de)
DK (1) DK1492766T3 (de)
ES (1) ES2286418T3 (de)
HK (1) HK1068138A1 (de)
NZ (1) NZ530854A (de)
PT (1) PT1492766E (de)
WO (1) WO2003087055A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136489A0 (en) * 1997-12-08 2001-06-14 Scripps Research Inst Synthesis of cc-1065/duocarmycin analogs
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CN101671335A (zh) * 2001-05-31 2010-03-17 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP1851250B1 (de) * 2005-02-18 2012-06-06 Medarex, Inc. Menschlicher monoklonaler antikörper gegen ein prostataspezifisches membranantigen
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
IL305084A (en) * 2005-08-24 2023-10-01 Immunogen Inc A process for preparing purified drug compounds
NZ566982A (en) * 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
ES2527961T3 (es) * 2005-09-26 2015-02-02 Medarex, L.L.C. Anticuerpos monoclonales humanos para CD70
PL1940789T3 (pl) * 2005-10-26 2012-04-30 Squibb & Sons Llc Metody i związki do otrzymywania analogów cc-1065
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1832577A1 (de) * 2006-03-07 2007-09-12 Sanofi-Aventis Verbesserte Pro-Pharmaka von CC-1065-Analoga
USRE47123E1 (en) * 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
EP1914242A1 (de) * 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
MX338185B (es) * 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
EP2121667B1 (de) 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Chemische verbinder mit einzelaminosäuren und konjugaten davon
WO2008115404A1 (en) * 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
EP2188311B1 (de) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Auf den egf-rezeptor zielender, monoklonaler antikörper 175 und derivate und anwendungen davon
EP2240516B1 (de) * 2007-12-26 2015-07-08 Biotest AG Verfahren und mittel zur verbesserten abzielung auf cd138-exprimierende tumorzellen
PL2801584T3 (pl) 2007-12-26 2019-12-31 Biotest Ag Środki mające za cel CD138 i ich zastosowania
CN101965366B (zh) * 2007-12-26 2016-04-27 生物测试股份公司 靶向cd138的免疫缀合物及其应用
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
KR20210100223A (ko) 2008-04-30 2021-08-13 이뮤노젠 아이엔씨 가교제 및 그 용도
LT2437790T (lt) 2009-06-03 2019-06-10 Immunogen, Inc. Konjugavimo būdai
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
JP2013506709A (ja) 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
KR20220009505A (ko) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
MX368966B (es) 2011-06-10 2019-10-23 Mersana Therapeutics Inc Conjugados de proteina-polimero-farmaco.
EP2788030B1 (de) 2011-12-08 2018-06-20 Biotest AG Verwendung von immunokonjugaten gegen cd138
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP2928503B1 (de) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Konjugate von auristatinverbindungen
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
JP6427564B2 (ja) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質−ポリマー−薬物共役体
EP3054991B1 (de) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
CN104860867B (zh) * 2015-04-23 2017-06-13 浙江大学 2,3‑二取代‑1H‑苯并[f]吲哚‑4,9‑二酮化合物及其制备法
EP3319936A4 (de) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. Brückenlinker zur konjugation von zellbindenden molekülen
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331569A1 (de) 2015-08-07 2018-06-13 Gamamabs Pharma Antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
EP3474901A1 (de) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Spaltbares, in der bioorthogonalen arzneimittelaktivierung verwendetes tetrazin
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3641826B1 (de) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Verfahren zur herstellung von wirkstofftragenden polymergerüsten und protein-polymer-wirkstoff-konjugaten
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
US20210308207A1 (en) 2018-05-04 2021-10-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
EA202191175A1 (ru) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
US20230121556A1 (en) 2019-06-17 2023-04-20 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
MX2022008437A (es) 2020-01-09 2022-08-19 Mersana Therapeutics Inc Conjugados fármaco-anticuerpo específicos de sitio con enlazadores que contienen péptidos.
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
CA3230774A1 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
EP4186529A1 (de) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104941A1 (en) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
WO2023158305A1 (en) 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes

Also Published As

Publication number Publication date
AU2003218060B2 (en) 2008-06-26
PT1492766E (pt) 2007-07-26
EP1492766A1 (de) 2005-01-05
WO2003087055A1 (en) 2003-10-23
ES2286418T3 (es) 2007-12-01
US7329760B2 (en) 2008-02-12
CA2456453C (en) 2010-08-17
US20030195365A1 (en) 2003-10-16
EP1492766B1 (de) 2007-05-02
JP4578105B2 (ja) 2010-11-10
NZ530854A (en) 2005-11-25
EP1492766A4 (de) 2005-12-14
US6586618B1 (en) 2003-07-01
CA2456453A1 (en) 2003-10-23
JP2005522506A (ja) 2005-07-28
ATE361278T1 (de) 2007-05-15
AU2003218060A1 (en) 2003-10-27
US6534660B1 (en) 2003-03-18
DK1492766T3 (da) 2007-09-10
DE60313595T2 (de) 2008-01-10
HK1068138A1 (en) 2005-04-22

Similar Documents

Publication Publication Date Title
DE60313595D1 (de) Verbesserte synthese von cc-1065-analoga
BR0016063A (pt) Métodos para a sìntese de alfentanila, sufentanila e remifentanila
ATE381557T1 (de) Rho-kinase inhibitoren
CY1118299T1 (el) Ανοσοκατασταλτικες ενωσεις και συνθεσεις
CY1109655T1 (el) Συνδεση των παραγωγων κινουκλιδινης στους μουσκαρινικους υποδοχεις μ3
ZA200410408B (en) N-substituted piperidine derivatives as serotonin receptor agents.
CY1105253T1 (el) Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως
HN2002000028A (es) Pirimidinas inhibidoras de metaloproteinasas
DE60021371D1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
CY1108547T1 (el) Αναλογα σωματοστατινης
CY1106359T1 (el) Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων
ATE452683T1 (de) 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3- methyl-5-oxo-4h-pyrazol-4-yliden hydrazino -2'- hydroxy- 1,1'-biphenyl -3-carbonsaure-bis- (monoethanolamin)
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1109760T1 (el) Παραγωγα ινδολης-3-θειου
DE60313289D1 (de) Kontrollierte synthese von ziprasidon
FI20031595A (fi) Järjestely pyörteiden muodostamiseksi
ITRM20020301A0 (it) Macchina per radioterapia intraoperatoria.
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
WO2004058392A3 (de) Intramolekular triplettsensibilisierte o-nitrophenylethyl-photoschutzgruppen
DE60212146D1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
AR028817A1 (es) Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
ATE297904T1 (de) Halo-alkoxycarbonylverbindungen
CY1105591T1 (el) Αναστολεις για συνθαση του 20-ηετε

Legal Events

Date Code Title Description
8364 No opposition during term of opposition